促动力药、胃轻瘫饮食或神经调节剂单用或联用对胃轻瘫症状的获益
本研究纳入129例有胃轻瘫症状的患者,行无线动力胶囊胃排空时间和胃排空闪烁显像检查,根据结果推荐治疗调整,并随访6个月评估GCSI及个体症状评分变化。结果显示促动力药单用新治疗对GCSI无改善,神经调节剂单用可降低GCSI及除恶心呕吐外的大部分症状,促动力药联合胃轻瘫饮食或神经调节剂可改善GCSI及大部分症状。
要点
- 促动力药作为单用新治疗对胃轻瘫症状的GCSI改善有限(P=0.95)
- 神经调节剂单用可降低GCSI(P=0.04)及除恶心呕吐外的大部分个体症状
- 促动力药联合胃轻瘫饮食或神经调节剂可改善GCSI(P≤0.04)及大部分个体症状
核心结论
- 促动力药作为单用新治疗对胃轻瘫症状获益有限;神经调节剂单用可改善除恶心呕吐外的症状,尤其在胃排空非延迟者中;在促动力药基础上加用胃轻瘫饮食或神经调节剂可缓解症状,提示联合治疗可能对管理这些患者更有用。
研究设计与样本
- 129例有胃轻瘫症状的患者接受无线动力胶囊胃排空时间和胃排空闪烁显像检查,根据检查结果推荐治疗调整,随访6个月,分析GCSI及个体症状评分变化与促动力药、胃轻瘫饮食或神经调节剂单用新治疗或双联组合推荐的关系,并进行多变量分析校正胃排空时间及其他变量。
主要发现
- 整个队列无论治疗如何,6个月内GCSI评分下降0.53分(四分位距-1.25至0.05;P<.0001)。
- 促动力药作为单用新治疗,GCSI无下降(P=0.95)。
- 神经调节剂作为单用治疗,GCSI评分下降(P=0.04),除恶心呕吐外所有个体症状改善(恶心呕吐P=0.86)。
- 促动力药联合胃轻瘫饮食或神经调节剂可改善GCSI评分(P≤0.04)及大部分个体症状。
- 多变量分析校正胃排空时间后,胃排空非延迟者使用神经调节剂作为单用新治疗时GCSI下降更明显(P=0.01);胃排空闪烁显像、性别、糖尿病和功能性消化不良不影响任何治疗的反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Prokinetics have limited effectiveness for treating symptoms of gastroparesis. Thus, alternative or adjunct therapies, such as gastroparesis diets or neuromodulators, are often prescribed. Their therapeutic benefits alone or in combination remain unclear. METHODS: One hundred and twenty-nine patients with symptoms of gastroparesis underwent wireless motility capsule gastric emptying time and gastric emptying scintigraphy. Based on test results, changes in therapy were recommended. Changes in Gastroparesis Cardinal Symptom Index (GCSI) and individual symptom scores over 6 months were related to recommendations for prokinetics, gastroparesis diet, or neuromodulators given as solo new therapies or in dual combinations. Multivariate analyses were performed to adjust for gastric emptying and other variables. RESULTS: In the whole group regardless of therapy, GCSI scores decreased by 0.53 points (interquartile range, -1.25 to 0.05; P < .0001) over 6 months. GCSI did not decrease for prokinetics as solo new therapy (P = .95). Conversely, neuromodulators as solo therapy decreased GCSI scores (P = .04) and all individual symptoms except nausea/vomiting (P = .86). Prokinetics combined with gastroparesis diets or neuromodulators improved GCSI scores (P ≤ .04) and most individual symptoms. Adjusting for gastric emptying time on multivariate analyses showed greater GCSI decreases for nondelayed emptying for neuromodulators as solo new therapy (P = .01). Gastric emptying scintigraphy, gender, diabetes, and functional dyspepsia did not influence responses to any treatment. CONCLUSIONS: Initiating prokinetics as solo new therapy had little benefit for patients with symptoms of gastroparesis. Neuromodulators as the only new therapy decreased symptoms other than nausea and vomiting, especially with nondelayed gastric emptying. Adding gastroparesis diets or neuromodulators to prokinetics offered relief, suggesting that combination therapies may be more useful in managing these patients. (ClinicalTrials.gov NCT02022826.).
引用
- Hasler WL, Lee AA, Moshiree B, et al. Benefits of Prokinetics, Gastroparesis Diet, or Neuromodulators Alone or in Combination for Symptoms of Gastroparesis. Clin Gastroenterol Hepatol. 2023. PMID: 37913936. doi:10.1016/j.cgh.2023.10.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。